Foundation Medicine (FMI) Misses Q2 EPS by 45c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
JMP Securities Downgrades Foundation Medicine (FMI) to Market Perform
July 30, 2015 6:51 AM EDTJMP Securities downgraded Foundation Medicine (NASDAQ: FMI) from Market Outperform to Market Perform and removed its price target (prior $57.00).
For an analyst ratings summary and ratings history on Foundation Medicine click here. For more ratings news on Foundation Medicine click here.
Shares of Foundation Medicine closed at $29.30 yesterday.
... MoreLoxo Oncology (LOXO), University of Colorado Cancer Center Announce Publication of LOXO-101 Phase 1 Data in TRK
July 27, 2015 3:56 PM EDTThe University of Colorado Cancer Center and Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development. Additional contributors to the paper include the Knight Cancer Institute at Oregon Health & Science University and Foundation Medicine, Inc. (Nasdaq:... More
